Juvenile Rheumatoid Arthritis - Pipeline Insight, 2025
Description
DelveInsight’s, “Juvenile Rheumatoid Arthritis - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Juvenile Rheumatoid Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Juvenile Rheumatoid Arthritis: Overview
Juvenile idiopathic arthritis (JIA), formerly known as juvenile rheumatoid arthritis, is the most common type of arthritis in children under 16. JIA is an autoimmune disorder where the body's immune system mistakenly attacks its own cells and tissues, causing inflammation in the joints. The exact causes are unknown, but both heredity and environmental factors seem to play a role, with a genetic tendency combined with a trigger like a virus causing the immune system to go awry. JIA can affect any joint, leading to persistent pain, swelling, stiffness and limited mobility, with symptoms varying in duration from a few months to many years. Treatment focuses on controlling pain and inflammation, improving function, and preventing joint damage.
The most common signs and symptoms of juvenile idiopathic arthritis (JIA) are joint pain, swelling, stiffness and limited mobility, often worse in the morning or after naps. Joints may appear red, warm and tender to the touch. Some children may experience high fever, swollen lymph nodes, rash on the trunk, fatigue, and appetite loss and eye inflammation. Symptoms can vary in severity and duration, with some children only having symptoms for a few months while others have them for many years. The number and type of joints affected depends on the specific subtype of JIA.
The diagnosis of juvenile idiopathic arthritis (JIA) is based on the child's medical history, physical examination, and laboratory tests. Doctors look for joint pain, swelling, stiffness, and limited range of motion that has lasted for at least 6 weeks in a child under 16 years old. They may order blood tests to check for markers of inflammation like erythrocyte sedimentation rate and C-reactive protein, as well as autoantibodies like rheumatoid factor and antinuclear antibodies. Imaging tests like X-rays or MRI scans can help rule out other conditions and detect joint damage. Since there is no single definitive test for JIA, the diagnosis is made by excluding other potential causes of the child's symptoms.
The treatment of juvenile idiopathic arthritis (JIA) aims to control pain, preserve joint function, and prevent long-term damage. The first-line medications are nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen to reduce inflammation. Disease-modifying antirheumatic drugs (DMARDs) such as methotrexate are often added if NSAIDs alone are insufficient. For severe cases, corticosteroids or biologic drugs that target specific inflammatory pathways may be used. Physical therapy is crucial to maintain joint mobility and muscle strength.
""Juvenile Rheumatoid Arthritis - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Juvenile Rheumatoid Arthritis pipeline landscape is provided which includes the disease overview and Juvenile Rheumatoid Arthritis treatment guidelines. The assessment part of the report embraces, in depth Juvenile Rheumatoid Arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Juvenile Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Juvenile Rheumatoid Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Juvenile Rheumatoid Arthritis Emerging Drugs
Further product details are provided in the report……..
Juvenile Rheumatoid Arthritis: Therapeutic Assessment
This segment of the report provides insights about the different Juvenile Rheumatoid Arthritis drugs segregated based on following parameters that define the scope of the report, such as:
Juvenile Rheumatoid Arthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Juvenile Rheumatoid Arthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Juvenile Rheumatoid Arthritis drugs.
Juvenile Rheumatoid Arthritis Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Juvenile Rheumatoid Arthritis: Overview
Juvenile idiopathic arthritis (JIA), formerly known as juvenile rheumatoid arthritis, is the most common type of arthritis in children under 16. JIA is an autoimmune disorder where the body's immune system mistakenly attacks its own cells and tissues, causing inflammation in the joints. The exact causes are unknown, but both heredity and environmental factors seem to play a role, with a genetic tendency combined with a trigger like a virus causing the immune system to go awry. JIA can affect any joint, leading to persistent pain, swelling, stiffness and limited mobility, with symptoms varying in duration from a few months to many years. Treatment focuses on controlling pain and inflammation, improving function, and preventing joint damage.
The most common signs and symptoms of juvenile idiopathic arthritis (JIA) are joint pain, swelling, stiffness and limited mobility, often worse in the morning or after naps. Joints may appear red, warm and tender to the touch. Some children may experience high fever, swollen lymph nodes, rash on the trunk, fatigue, and appetite loss and eye inflammation. Symptoms can vary in severity and duration, with some children only having symptoms for a few months while others have them for many years. The number and type of joints affected depends on the specific subtype of JIA.
The diagnosis of juvenile idiopathic arthritis (JIA) is based on the child's medical history, physical examination, and laboratory tests. Doctors look for joint pain, swelling, stiffness, and limited range of motion that has lasted for at least 6 weeks in a child under 16 years old. They may order blood tests to check for markers of inflammation like erythrocyte sedimentation rate and C-reactive protein, as well as autoantibodies like rheumatoid factor and antinuclear antibodies. Imaging tests like X-rays or MRI scans can help rule out other conditions and detect joint damage. Since there is no single definitive test for JIA, the diagnosis is made by excluding other potential causes of the child's symptoms.
The treatment of juvenile idiopathic arthritis (JIA) aims to control pain, preserve joint function, and prevent long-term damage. The first-line medications are nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen to reduce inflammation. Disease-modifying antirheumatic drugs (DMARDs) such as methotrexate are often added if NSAIDs alone are insufficient. For severe cases, corticosteroids or biologic drugs that target specific inflammatory pathways may be used. Physical therapy is crucial to maintain joint mobility and muscle strength.
""Juvenile Rheumatoid Arthritis - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Juvenile Rheumatoid Arthritis pipeline landscape is provided which includes the disease overview and Juvenile Rheumatoid Arthritis treatment guidelines. The assessment part of the report embraces, in depth Juvenile Rheumatoid Arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Juvenile Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Juvenile Rheumatoid Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Juvenile Rheumatoid Arthritis.
This segment of the Juvenile Rheumatoid Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Juvenile Rheumatoid Arthritis Emerging Drugs
- Baricitinib: Eli Lilly and Company
- MP-1032: MetrioPharm
Further product details are provided in the report……..
Juvenile Rheumatoid Arthritis: Therapeutic Assessment
This segment of the report provides insights about the different Juvenile Rheumatoid Arthritis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Juvenile Rheumatoid Arthritis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Juvenile Rheumatoid Arthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Juvenile Rheumatoid Arthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Juvenile Rheumatoid Arthritis drugs.
Juvenile Rheumatoid Arthritis Report Insights
- Juvenile Rheumatoid Arthritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Juvenile Rheumatoid Arthritis drugs?
- How many Juvenile Rheumatoid Arthritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Juvenile Rheumatoid Arthritis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Juvenile Rheumatoid Arthritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Juvenile Rheumatoid Arthritis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eli Lilly and Company
- MetrioPharm
- Amgen
- Sunshine Guojian Pharmaceutical
- GENERIUM Pharmaceuticals
- UCB
- Baricitinib
- MP-1032
- Apremilast
- SSGJ-613
- GNR 086
- Certolizumab
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Juvenile Rheumatoid Arthritis: Overview
- Causes
- Etiology
- Signs and Symptoms
- Disease Treatment/Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Juvenile Rheumatoid Arthritis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Baricitinib: Eli Lilly and Company
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- MP-1032: MetrioPharm
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Juvenile Rheumatoid Arthritis Key Companies
- Juvenile Rheumatoid Arthritis Key Products
- Juvenile Rheumatoid Arthritis- Unmet Needs
- Juvenile Rheumatoid Arthritis- Market Drivers and Barriers
- Juvenile Rheumatoid Arthritis- Future Perspectives and Conclusion
- Juvenile Rheumatoid Arthritis Analyst Views
- Juvenile Rheumatoid Arthritis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
